These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15857828)

  • 21. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.
    Günther T; Culler M; Schulz S
    Mol Endocrinol; 2016 Apr; 30(4):479-90. PubMed ID: 26967369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
    Ferrante E; Pellegrini C; Bondioni S; Peverelli E; Locatelli M; Gelmini P; Luciani P; Peri A; Mantovani G; Bosari S; Beck-Peccoz P; Spada A; Lania A
    Endocr Relat Cancer; 2006 Sep; 13(3):955-62. PubMed ID: 16954443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat isolated distal colonic mucosa.
    McKeen ES; Feniuk W; Humphrey PP
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):402-11. PubMed ID: 8532068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
    Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
    Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptors in pituitary function, diagnosis and therapy.
    Hofland LJ; Lamberts SW
    Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug design at peptide receptors: somatostatin receptor ligands.
    Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
    J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
    Siehler S; Seuwen K; Hoyer D
    Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization.
    Durán-Prado M; Bucharles C; Gonzalez BJ; Vázquez-Martínez R; Martínez-Fuentes AJ; García-Navarro S; Rhodes SJ; Vaudry H; Malagón MM; Castaño JP
    Endocrinology; 2007 Jan; 148(1):411-21. PubMed ID: 17053026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
    Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
    Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
    Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A; Mantovani G; Spada A
    Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
    Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion.
    Luque RM; Durán-Prado M; García-Navarro S; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
    Endocrinology; 2006 Jun; 147(6):2902-8. PubMed ID: 16543371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.
    Petrucci C; Cervia D; Buzzi M; Biondi C; Bagnoli P
    Br J Pharmacol; 2000 Feb; 129(3):471-84. PubMed ID: 10711345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
    Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
    Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.